Tempus AI, Inc. (TEM)

Market Cap	13.53B
Revenue (ttm)	951.98M
Net Income (ttm)	-199.73M
Shares Out	173.73M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,239,568
Open	76.93
Previous Close	79.23
Day's Range	74.59 - 78.46
52-Week Range	31.36 - 97.79
Beta	n/a
Analysts	Buy
Price Target	70.17 (-9.89%)
Earnings Date	Nov 3, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jun 14, 2024
• Employees: 2,400
• Stock Exchange: NASDAQ
• Ticker Symbol: TEM
• Website: https://www.tempus.com

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $70.17, which is a decrease of -9.89% from the latest price.

Price Target

$70.17

(-9.89% downside)

Analyst Consensus: Buy